

Subject **Update on Collaboration with Other Organisations**

Agenda item **13**

Category **For Information**

Executive Summary

The purpose of this paper is to provide an update on Gavi’s collaboration and recent engagement with other global and regional health institutions. This includes: i) an update on Gavi’s engagement with the Lusaka Agenda with a focus on Gavi’s collaboration with GPEI; ii) an update on Gavi’s enhanced collaboration across four workstreams (malaria, health systems strengthening (HSS), country engagement, enabling functions and operations) with a fifth under development (tuberculosis) with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) and the Global Financing Facility (GFF); iii) the formation and readout from the first meeting of the ‘Joint Committee Working Group’; and iv) a summary of engagement with the African Union (AU) and Africa Centres for Disease Control and Prevention (Africa CDC), including the finalisation of the Africa CDC Grant Agreement and the launch of its programme of work. This paper builds on recent discussions including the October 2024 meeting of the Programme and Policy Committee (PPC), and the previous June 2024 governance cycle. Other related topics at the December 2024 Board meeting include CEO Update, including Strategy, Programmes and Partnerships; Health Systems Strategy; and Gavi 6.0 Operationalisation (evolution of the partnership approach, 6.0 measurement framework).

Action Requested of the Board

This report is for discussion only.

Next steps/timeline

Gavi will continue to collaborate with the Global Fund and the GFF to drive progress across the four priority workstreams with close sponsorship from the Gavi CEO, Global Fund Executive Director and GFF Director and regular updates to the Joint Committee Working Group, Board and Committees as relevant. Gavi will also continue to collaborate with Africa CDC on implementation of the Grant Agreement as well as African Vaccine Manufacturing Accelerator (AVMA) and the mpox response, and these collaborations will inform the evolution of Gavi’s operating and partnership model in Gavi 6.0.

Previous Board Committee or Board deliberations related to this topic

In October 2024 Programme and Policy Committee meeting book: Doc 10 Update on Collaboration with Other Organisations.

In June 2024 Board meeting book: Doc 08 Update on Collaboration with Other Organisations.

In May 2024 Programme and Policy Committee meeting book: Doc 04 Update on Collaboration with Other Organisations.

In April 2024 Joint Gavi and Global Fund Board Special Session on malaria: Slides circulated following the session.

In December 2023 Board meeting book: Doc 03 CEO Report - the Board received an update on the Future for Global Health Initiatives and Lusaka Agenda.

In December 2023 Board meeting book: Doc 10 Gavi's Role in Pandemic Prevention, Preparedness and Response (PPPR) – *the Board approved: i) funding to support capacity building for a coalition of vaccine partners; and ii) AVMA and acknowledged Africa CDC's important role and their demonstrated commitment as co-host of the event to launch the AVMA).*

Report

1. Update on how Gavi is taking forward the Lusaka Agenda

1.1 Gavi was a core partner of the Future of Global Health Initiatives (FGHI) process which culminated in the Lusaka Agenda in 2023. The Lusaka Agenda has identified five key shifts to stimulate the evolution of the health ecosystem. Much of Gavi's work, both ongoing and planned, aligns with and contributes to the Lusaka Agenda (slide below is illustrative not exhaustive):

Gavi's alignment with the Lusaka Agenda's '5 Shifts'

1. Making a stronger contribution to PHC

- Immunisation is often the pathfinder to bring access to health care to missed communities and new 6.0 strategy and draft health systems strategy strongly align Zero Dose approach to integrate with broader PHC (e.g. HMS, supply chain, service delivery, trained health care worker)
- Promoting domestic resources for immunization and PHC is part of Gavi's Strategic Goal 3
- Gavi's Full Portfolio Planning process aligns behind country plans (National Immunization Strategy (NIS), disease prevention and control plans, cMYP) + under EVOLVE testing programming based on NIS
- Participate in pooled funding mechanisms to ensure alignment behind country plans for PHC
- A key principle of the 6.0 strategy is the focus on integration of immunization with PHC in support of universal health coverage

2. Catalytic role towards sustainability

- Co-financing central to Gavi's model: 19 countries fully transitioned and financing own vaccine programme; by end 2025 countries supported by Gavi will have invested approx. \$5.2B in their vaccine programmes since 2008
- Catalytic support to MICs and transitioned countries to help ensure gains are sustained
- High-level political advocacy with MOH and MOF supported by Alliance partners and local CSOs
- Intensive market shaping efforts drive down price and foster healthy markets supporting sustainability of programmes
- Board approved target to increase investments directly through governments + Board approved strategy and funding to strengthen country financial management capacities

3. Joint approaches in achieving equity

- ZD is a critical metric for equity, highlighting communities largely missed by health systems and this has been increasingly adopted by other agencies (e.g., through Global Action Plan, WB projects etc.) as a key equity measure for PHC
- Equity is at the heart of Gavi 5.1 and 6.0 with coherence in approach across Alliance partners
- Dedicated mission indicators and targets aligned with IA2030
- EAF, ZIP, ZD LEARN, Big Catchup, MICs all cross-Alliance approaches working with countries to achieve equity
- Gender policy and gender responsive programming addressing gender dimensions of equity
- Global and regional coordination mpox vaccine allocation strive for equity

4. Achieve strategic & operational coherence

- Alliance Partnership model driving coherence across partners
- Longstanding Gavi and TGF joint support for Programme Management Units to strengthen financial management
- Budget templates aligned to country categories
- Streamlining of our grant management through EVOLVE
- Working in close collaboration with AU/CDC through MOU and workplan
- Continue to elevate country voices and consultation in Board and governance functions
- Gavi-GF-GFF enhanced collaboration workstreams in addition to ongoing / existing collaboration (e.g. HMS, PFM, supply chain)
- [TBC] Consolidation of funding levers

5. Coordinated approach to products, R&D and regional manufacturing

- CEPI, WHO, Gavi, UNICEF partnership on end-to-end vaccine response to outbreaks
- Collaborative development of AVMA and support for regional manufacturing
- Early market shaping for diseases such as Ebola Sudan and Marburg to accelerate early access
- VIS as a highly consultative prioritization mechanism with priorities agreed across all Alliance Partners

2 Presentation Footer



1.2 At the International Conference on Public Health in Africa in 2023 in Lusaka, **Africa CDC** announced it would **lead next steps for the Lusaka Agenda across the region**. Gavi supports Africa CDC's regional leadership of the Lusaka Agenda and is working with Africa CDC to ensure that all enhanced GHI collaboration activities support the principles and objectives of the Lusaka agenda. **Gavi staff have actively participated in a number of discussions to further the Lusaka Agenda** including Africa CDC's June 2024 technical consultation in Addis Adaba and the session at the WHO Africa Regional Office Regional Committee in Brazzaville in August 2024, presenting on behalf of the enhanced GHI collaboration on progress to date. This provided the opportunity to emphasise the GHIs' readiness to align efforts with the Lusaka Agenda and underscored the commitment to supporting Africa's health priorities. Gavi's CEO also participated in the Lusaka Agenda convening in New York in September 2024 on the sidelines of the UN General Assembly.

1.3 A related collaboration of interest among PPC members is **Gavi's collaboration with the Global Polio Eradication Initiative (GPEI)** on strategic and programmatic issues, especially **alignment and integration at the country level**. As a core member of GPEI, Gavi plays a vital role in

providing vaccine support in routine immunisation programmes and strengthening immunisation delivery to reach un- and under-immunised communities and children, including in polio high-risk countries. Gavi supports the introduction and roll-out of inactivated polio vaccine (IPV) – initially IPV1 – into the national immunisation programmes of 71 countries, and now a second IPV dose as recommended by WHO. In December 2023, Gavi introduced support for the hexavalent vaccine, an important tool in looking toward a polio-free world. In addition, there are concerted efforts to advocate for and facilitate the co-delivery of bOPV (financed by GPEI) with planned, Gavi-supported supplementary immunisation activities, such as measles/measles-rubella campaigns and the Big Catch-up, to enhance polio eradication efforts and promote integration. Discussions are also under way to recruit a time-limited secondment to the Secretariat to more deliberately support efforts to further bring together Gavi programming and polio eradication efforts in select geographies. Gavi and GPEI partners are both part of the Health Campaign Effectiveness Coalition (HCE), which seeks to make health campaigns more collaborative, integrated, equitable, and efficient, aligning with the Lusaka Agenda's goals for universal health coverage and resilient health systems. A joint Polio Oversight Board and Gavi Board session is being scheduled for Q2 2025 to increase momentum for improved collaboration between Gavi and GPEI, with the aim of aligning on priorities to advance shared polio and immunisation goals, including during the post-certification period.

2. Update on Gavi, Global Fund, and Global Financing Facility Enhanced Collaboration

- 2.1 The Lusaka Agenda laid out a set a discrete set of near term priorities **for global health institutions (GHIs) as sub-set of the broader mandate which are being addressed through the enhanced collaboration effort among Gavi, Global Fund and the Global Financing Facility (“enhanced GHI collaboration”)**, including: i) developing a 24-month workplan and operationalisation shared with the governing bodies; ii) establishing a joint committee mechanism between Gavi, Global Fund and GFF to guide cross- board collaboration and action iii) engaging a set of pathfinder countries for joint engagement to deliver on near-term priorities; and iv) engagement in a joint vision for market shaping research and development and manufacturing.
- 2.2 **Gavi and the Global Fund initiated an enhanced collaboration initiative in October of 2023 and have a history of collaboration that pre-dates the current initiative** including information sharing, coordination on advocacy and communications, and joint investments in countries, resulting in tangible results at country level (e.g. support for Logistics Management Information and DHIS- 2 government data systems, working through joint Programme Management Units (PMUs), reductions in severe malaria and all-cause mortality in children through the Malaria Vaccine Implementation Pilots) **and the two GHIs have been co-located at the Global Health Campus since**

2018 providing opportunities for increased operational efficiencies (facilities management, shared IT support services, travel, health and security).

2.3 Both Gavi and the Global Fund have their own existing areas of collaboration with the Global Financing Facility (GFF). Gavi's existing collaboration with GFF is focused on country-level data strengthening, including rapid cycle monitoring and data use, data quality assessment and Health Management Information System strengthening, joint approaches to gender responsive monitoring, civil society organisation (CSO) engagement in health financing and engagement in joint financing with the World Bank. In bringing the three GHIs together, there is an opportunity to further align in our support to countries based on the three principles of our collaboration: i) GHI efforts are to be country led and demand driven; ii) use of a differentiated approach that leverages the strengths of each GHI; and iii) consideration is to be given for operating modalities of each GHI (e.g. funding processes, operational approaches).

2.4 The enhanced GHI collaboration is organised into four key workstreams including: i) country engagement; ii) HSS; iii) malaria; and iv) back office and enabling functions, noting that there are many interdependencies across these workstreams and Gavi's engagement at country level must be tailored and unique to each country context. **There is also a fifth and emerging workstream on tuberculosis** which will build on early lessons from the malaria collaboration workstream. Updates on the workstreams are included in Annex A, a mapping of the existing in-country collaboration across the GHIs in wave 1 countries are included in Annex B, and newly finalised Gavi-Global Fund joint guidance on the use of respective resources around malaria vaccine introduction in Annex C.

3. Joint Committee Working Group (JCWG)

3.1 By the time of the Board, the JCWG will have met twice. The first meeting of the JCWG took place on 1 October 2024 and focused on the forming of the group including a discussion on the TORs and related ways of working. The second meeting of the JCWG will take place on 26 November 2024 and will focus on the workstreams. Any key updates from the second JCWG will be provided during the presentation of this item at the Board meeting in December 2024.

3.2 During the first meeting, JCWG members reaffirmed the mandate of the group, and there was general agreement on the need to improve how the GHIs work together in support of countries, and to get concrete on the areas where the GHIs overlap or could better leverage one another's respective competencies and investments. It was discussed that the entry point for these discussions would be through the workstreams. It was noted that this is not a decision-making body, but rather an advisory body to the GHIs with the respective Committees and Boards of each of the GHIs retaining their

mandated roles. The group decided to move forward with the selection of co-chairs and agreed that the meeting cadence should be more frequent with greater engagement particularly in the early stages. There was also a question on the representative nature of the members of the working group with general agreement that they would each bring the broader perspective of their institution's participation across the various governing bodies of the GHIs. The working group also discussed the potential for the inclusion of additional members, ultimately deciding not to expand membership at this time but to invite relevant actors based on the agenda and seek collaboration at the operational level. The working group emphasised the importance that this effort feed into and be complementary to the broader Lusaka Agenda and the leadership of Africa CDC on the African continent, including their work on the exemplar countries, while noting the need for the JCWG to stay focused on the collaboration across the three GHIs.

3.3 Composition of the JCWG:

Gavi/GFF/GF JCWG (Governance Membership)

GHI	Name	Country/Org.	Constituent Group	Governance group
Gavi	H.E Mekdes Daba	Ethiopia	Implementing	Board
	Mohamed Jama	Somalia	Implementing	Board, Programme and Policy Committee
	Bvudzai Magadzire	Village Reach	Civil Society	Board
	Frode Forland	Norway	Donor	Board
	Pavani Ram	United States	Donor	Programme and Policy Committee
GFF	Sue Graves	Gates Foundation	Donor	Trust Fund Committee
	Gerald Manthala	Malawi	Implementing	Investors Group
	Oyeyemi Pitan	Nigeria youth rep.	Civil Society	Investors Group
Global Fund	Oumar Mele Djalo Boukou	Western Central Africa	Implementing	Strategy Committee
	Sarah Boulton	United Kingdom	Donor	Strategy Committee
	Carolyn Gomes	Developing country NGO	Civil Society	Strategy Committee
	Harriet Ludwig	Germany	Donor	Strategy Committee
	Jim Tulloch	Western Pacific Region	Implementing	Strategy Committee

Constituency representation

of donor groups 5
of implementing countries 5
of civil society: 3

Geographic country representation

of continents represented: 4

3

4. New phase of collaboration between Gavi, African Union and Africa CDC

4.1 Building on a strong history of collaboration, the relationship between Gavi, the AU, and Africa CDC has entered a new phase focused on implementation during the last months. This pivot is most notable in three areas: i) the launch of the African Vaccine Manufacturing Accelerator (AVMA); ii) the operationalisation of the priority areas agreed in the May 2023 Memorandum of Understanding (MOU); and iii) the response to the monkey pox (mpox) outbreak.

- 4.2 With respect to AVMA, and after the successful launch that took place in June 2024 in Paris, France, Africa CDC and Gavi are working closely in multiple areas including co-hosting an annual Vaccine and Health Products Manufacturing Forum for African Union member states.
- 4.3 In July 2024, Africa CDC and Gavi signed a US\$ 12 million grant agreement to support implementation of several priorities agreed in the May 2023 MOU, namely strengthening routine immunisation, building public trust in vaccines, Africa vaccine manufacturing, and pandemic preparedness, prevention, and response. The grant is grounded on the notion that a strong Africa CDC institution is critical to sustainable immunisation programmes in Africa in the long-term and involved a robust design and consultation process to promote complementarity and ensure activities support jointly shared Africa CDC and Gavi objectives. Implementation will leverage the Project Implementation Unit (PIU) established by the World Bank to streamline project management functions while building Africa CDC capacities. Activities were formally launched at a kick-off meeting in August 2024 involving Alliance partners, and reporting on implementation is required semi-annually. Gavi recently completed a Program Capacity Assessment to confirm Africa CDC's capability to exercise strong stewardship over Gavi-funded support. Further details will be shared at the next governance cycle in 2025. Finally, as discussed in Doc 07, the Gavi Alliance response to mpox is fully supportive of Africa CDC's leadership and involves intense collaboration across several levels of the respective organisations. Gavi has directly contributed to Africa CDC's efforts including by funding several headcounts focused on mpox via the Grant Agreement.

Annexes

Annex A: Workstream Updates

Annex B: Mapping of Existing Collaboration in Wave 1 Countries

Annex C: Gavi and Global Fund Joint Guidance for Use of Respective Resources Around Malaria Vaccine Introduction

Additional information available on BoardEffect

Appendix 1: Pre-read deck for the first meeting of the Joint Committee Working Group

Appendix 2: Pre-read deck for the second meeting of the Joint Committee Working Group